摘要
目的探讨TAC方案(多西他赛+吡柔比星+环磷酰胺)新辅助化疗对乳腺癌根治术患者近期疗效及血清糖类抗原153(carbohydrate antigen 153,CA153)和细胞角蛋白19片段抗原21-1(cytokeratin-19-fragment antigen 21-1,CYFRA21-1)水平的影响。方法选择2017年10月至2019年10月于梧州市工人医院行乳腺癌根治术的68例患者为研究对象,根据患者接受的不同新辅助化疗方案将其分为观察组和对照组,每组各34例。对照组患者行FAC方案(氟尿嘧啶+吡柔比星+环磷酰胺)新辅助化疗,观察组患者行TAC方案新辅助化疗。两组均以21 d为1个疗程,连续化疗4个疗程后评价疗效。比较两组患者近期疗效、新辅助化疗后生存质量改善情况、新辅助化疗前后血清CA153和CYFRA21-1水平及新辅助化疗期间不良反应发生情况。结果观察组患者治疗总有效率和新辅助化疗后生存质量提高率均显著高于对照组(均P<0.05)。两组患者新辅助化疗后血清CA125和CYFRA21-1水平均显著低于本组新辅助化疗前(均P<0.05),观察组患者新辅助化疗后血清CA125和CYFRA21-1水平均显著低于对照组(均P<0.05)。两组患者新辅助化疗期间不良反应发生率比较差异均无统计学意义(均P>0.05)。结论TAC方案新辅助化疗对乳腺癌根治术患者近期疗效良好,可改善患者生存质量,降低血清CA153和CYFRA21-1水平,不良反应少,用药安全性良好。
Objective To investigate the effect of TAC regimen(docetaxel+hydrochloride+cyclophosphamide)neoadjuvant chemotherapy on the short-term curative effect and the levels of serum carbohydrate antigen 153(CA153)and cytokeratin-19-fragment antigen 21-1(CYFRA21-1)of breast cancer patients undergoing radical mastectomy.Method A total of 68 patients who underwent radical mastectomy in Gongren Hospital of Wuzhou from October 2017 to October 2019 were selected as the research objects,they were divided into observation group(34 cases)and control group(34 cases)according to the different neoadjuvant chemotherapy regimens.Patients in control group received FAC regimen(fluorouracil+hydrochloride+cyclophosphamide)neoadjuvant chemotherapy,patients in observation group received TAC neoadjuvant chemotherapy.21 days as a course of treatment,continuous chemotherapy for 4 cycles to evaluate the efficacy.The short-term curative effect,the improvement of quality of life after neoadjuvant chemotherapy,the changes of serum CA153 and CYFRA21-1 levels before and after neoadjuvant chemotherapy,and the adverse reactions during neoadjuvant chemotherapy were compared between the two groups.Result The total effective rate and the improvement rate of quality of life after neoadjuvant chemotherapy in observation group were significantly higher than those in control group(all P<0.05).The levels of serum CA125 and CYFRA21-1 after neoadjuvant chemotherapy in the two groups were significantly lower than those before neoadjuvant chemotherapy(all P<0.05),while those in observation group were significantly lower than those in control group(all P<0.05).There was no significant difference in the incidence of adverse reactions during neoadjuvant chemotherapy between the two groups(all P>0.05).Conclusion TAC neoadjuvant chemotherapy has a good shortterm effect on breast cancer patients undergoing radical mastectomy.It can improve the quality of life of patients,reduce the serum CA153 and CYFRA21-1 levels,with less adverse reactions and good drug safety.
作者
叶大才
陈潇
梁明飞
华若岳
莫辉
江小龙
Ye Dacai;Chen Xiao;Liang Mingfei;Hua Ruoyue;Mo Hui;Jiang Xiaolong(Department of General Surgery,Gongren Hospital of Wuzhou,Guangxi,Wuzhou 543000,China)
出处
《中国医学前沿杂志（电子版）》
2020年第7期76-79,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
广西壮族自治区计划课题(Z20170117)。
